• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke(CONVINCE):a randomised controlled trial

摘要:

Background:Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease,which is typically caused by atherosclerosis,ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke.Methods:We did a randomised,parallel-group,open-label,blinded endpoint assessed trial comparing long-term colchicine (0.5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe,non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible. The primary endpoint was a composite of first fatal or non-fatal recurrent ischaemic stroke,myocardial infarction,cardiac arrest,or hospitalisation (defined as an admission to an inpatient unit or a visit to an emergency department that resulted in at least a 24 h stay[or a change in calendar date if the hospital admission or discharge times were not available]) for unstable angina. The p value for significance was 0.048 to adjust for two prespecified interim analyses conducted by the data monitoring committee,for which the steering committee and trial investigators remained blinded. The trial was registered at ClinicalTrials.gov (NCT02898610) and is completed.Findings:3154 patients were randomly assigned between Dec 19,2016,and Nov 21,2022,with the last follow-up on Jan 31,2024. The trial finished before the anticipated number of outcomes was accrued (367 outcomes planned) due to budget constraints attributable to the COVID-19 pandemic. Ten patients withdrew consent for analysis of their data,leaving 3144 patients in the intention-to-treat analysis:1569 (colchicine and usual care) and 1575 (usual care alone). A primary endpoint occurred in 338 patients,153 (9.8%) of 1569 patients allocated to colchicine and usual care and 185 (11.7%) of 1575 patients allocated to usual care alone (incidence rates 3.32 vs 3.92 per 100 person-years,hazard ratio 0.84;95% CI 0.68-1.05,p=0.12). Although no between-group difference in C-reactive protein (CRP) was observed at baseline,patients treated with colchicine had lower CRP at 28 days and at 1,2,and 3 years (p<0.05 for all timepoints). The rates of serious adverse events were similar in both groups.Interpretation:Although no statistically significant benefit was observed on the primary intention-to-treat analysis,the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials.

更多
作者: Peter Kelly
DOI: 10.1016/S0140-6736(24)00968-1
发布时间: 2024-07-08
  • 浏览:0
  • 下载:0

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
manbet官网登录 小程序
new翻译 充值 订阅 收藏 移动端

官方微信

manbet官网登录 小程序

使用
帮助
Alternate Text
调查问卷